Literature DB >> 14522887

Tumor promotion by Mdm2 splice variants unable to bind p53.

Jordan S Fridman1, Eva Hernando, Michael T Hemann, Elisa de Stanchina, Carlos Cordon-Cardo, Scott W Lowe.   

Abstract

The Mdm2 oncoprotein physically associates with p53 and antagonizes its tumor suppressor functions. Previous studies indicate that some tumors express alternatively or aberrantly spliced Mdm2 variants that are unable to bind p53, but whether these actively contribute to carcinogenesis or are a byproduct of cancer progression has been unclear. In this study, we examined the ability of full-length Mdm2 and several tumor-derived splice variants to modulate tumor development in E micro -myc transgenic mice. We report that several tumor-derived Mdm2 splice variants promote tumorigenesis in a manner that is comparable with full-length Mdm2. Our results imply that the current paradigm for understanding Mdm2 action during oncogenesis is incomplete, and its splice variants contribute to human cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522887

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

2.  Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4.

Authors:  Chuandong Fan; Xinjiang Wang
Journal:  Cell Cycle       Date:  2017-02-06       Impact factor: 4.534

3.  MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.

Authors:  Lenora W M Loo; Chong Gao; Yurii B Shvetsov; Danielle R Okoro; Brenda Y Hernandez; Jill Bargonetti
Journal:  Breast Cancer Res Treat       Date:  2018-11-23       Impact factor: 4.872

Review 4.  The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor.

Authors:  James J Manfredi
Journal:  Genes Dev       Date:  2010-08-01       Impact factor: 11.361

5.  A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Authors:  Sophia Adamia; Benjamin Haibe-Kains; Patrick M Pilarski; Michal Bar-Natan; Samuel Pevzner; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; John Burke; Ilene Galinsky; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Richard Stone; James D Griffin
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

6.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

Review 7.  MdmX regulates transformation and chromosomal stability in p53-deficient cells.

Authors:  Zdenka Matijasevic; Anna Krzywicka-Racka; Greenfield Sluder; Stephen N Jones
Journal:  Cell Cycle       Date:  2008-10-15       Impact factor: 4.534

8.  Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions.

Authors:  Takehiko Shiraishi; Jonhard Eysturskarth; Peter E Nielsen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

9.  Using Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis.

Authors:  Hugh S Gannon; Stephen N Jones
Journal:  Genes Cancer       Date:  2012-03

10.  MDM4 (MDMX) and its Transcript Variants.

Authors:  F Mancini; G Di Conza; F Moretti
Journal:  Curr Genomics       Date:  2009-03       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.